Cargando…
Development of a PBPK model to quantitatively understand absorption and disposition mechanism and support future clinical trials for PB‐201
PB‐201 is the second glucokinase activator in the world to enter the phase III clinical trials for the treatment of type 2 diabetes mellitus (T2DM). Combined with the efficacy advantages and the friendly absorption, distribution, metabolism, and excretion characteristics, the indication population o...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349193/ https://www.ncbi.nlm.nih.gov/pubmed/37078371 http://dx.doi.org/10.1002/psp4.12964 |